Ewing Sarcoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 88 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Ewing Sarcoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Ewing Sarcoma - Pipeline Review, H2 2014', provides an overview of the Ewing Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ewing Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ewing Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ewing Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ewing Sarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Ewing Sarcoma - Overview 9
Pipeline Products for Ewing Sarcoma - Comparative Analysis 10
Ewing Sarcoma - Therapeutics under Development by Companies 11
Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes 13
Ewing Sarcoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Ewing Sarcoma - Products under Development by Companies 16
Ewing Sarcoma - Products under Investigation by Universities/Institutes 17
Ewing Sarcoma - Companies Involved in Therapeutics Development 18
Shionogi & Co., Ltd. 18
Amgen Inc. 19
GlaxoSmithKline plc 20
Daiichi Sankyo Company, Limited 21
Sigma-Tau S.p.A. 22
Merrimack Pharmaceuticals, Inc. 23
Pharma Mar, S.A. 24
Bellicum Pharmaceuticals, Inc. 25
Gradalis Inc. 26
Tesaro, Inc. 27
EntreChem, S.L. 28
Oncomatrix, S.L. 29
Ewing Sarcoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ganitumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PM-00104 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
exatecan mesylate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pazopanib hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
niraparib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
irinotecan sucrosofate liposomal - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
FANG Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Dendritic Cell Therapy for Oncology - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
S-588410 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SST-0001 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecule to Inhibit LSD-1 for Ewing Sarcoma - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
dactinomycin reformulation - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
EC-8105 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CytoPep - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MTX2-NIG - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Ewing Sarcoma - Recent Pipeline Updates 68
Ewing Sarcoma - Dormant Projects 81
Ewing Sarcoma - Discontinued Products 82
Ewing Sarcoma - Product Development Milestones 83
Featured News & Press Releases 83
Nov 26, 2012: Possible New Treatment for a Childhood Cancer 83
Apr 16, 2012: EntreChem's Mithramycin Analog EC-8042 Shows Increased Potency And High Selectivity For Treatment Of Sarcoma 84
Apr 16, 2012: EntreChem's Mithramycin Shows Increased Potency And Higher Selectivity For Treatment Of Sarcoma 84
Mar 31, 2012: Researchers State Combination Of Two Targeted Therapies Act Against Ewing's Sarcoma Tumors 84
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88

List of Tables
Number of Products under Development for Ewing Sarcoma, H2 2014 9
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2014 18
Ewing Sarcoma - Pipeline by Amgen Inc., H2 2014 19
Ewing Sarcoma - Pipeline by GlaxoSmithKline plc, H2 2014 20
Ewing Sarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 21
Ewing Sarcoma - Pipeline by Sigma-Tau S.p.A., H2 2014 22
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 23
Ewing Sarcoma - Pipeline by Pharma Mar, S.A., H2 2014 24
Ewing Sarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2014 25
Ewing Sarcoma - Pipeline by Gradalis Inc., H2 2014 26
Ewing Sarcoma - Pipeline by Tesaro, Inc., H2 2014 27
Ewing Sarcoma - Pipeline by EntreChem, S.L., H2 2014 28
Ewing Sarcoma - Pipeline by Oncomatrix, S.L., H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Ewing Sarcoma Therapeutics - Recent Pipeline Updates, H2 2014 68
Ewing Sarcoma - Dormant Projects, H2 2014 81
Ewing Sarcoma - Discontinued Products, H2 2014 82